

Ernesto Maddaloni, MD, PhD

CURRENT POSITION (S)

Since 2021 - Assistant Professor (RTDB SC 06/D2, SSD MED13) Dept. of Experimental Medicine, “Sapienza” University of Rome, Italy

Since 2021 - Research Associate, Diabetes Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK.

BIBLIOMETRIC INDEXES (SCOPUS), RETRIEVED ON

- a. Citations: 2221
- b. Documents: 97
- c. h-index: 26
- d. International collaboration (%): 38.1%
- e. Academic-Corporate collaboration (%): 2.4%
- f. Documents in top citation percentiles: 48 document (57.1%)
- g. Documents in top 25% journals by CiteScore percentile: 64 documents (77.1%)
- h. Documents and Field-Weighted Citation Impact: 1.75
- i. Most contributed Topics last 5 years (2019–2023): the first three
 - 1. Latent Autoimmune Diabetes in Adults; Zinc Transporter 8; Autoantibodies; (T.1787)
 - 2. Radiological Findings; Clinical Features; COVID-19; (T.1100120)
 - 3. Antidiabetic Agent; Empagliflozin; Electron Microprobe Analysis; (T.2586)
- j. Author Position last 10 years (2014-2023):
 - i. First author: 33%; 26 documents; average citation: 33; FWCI: 2.465)
 - ii. Last Author: 10%; 8 documents; average citation: 35; FWCI: 1.447)
 - iii. Co-author: 56%; 45 documents; average citation: 22; FWCI: 1.536)

WORK EXPERIENCE
EDITORIAL ACTIVITY

-
- 2022- Present **Associate Editor for Diabetes/Metabolism Research and Reviews**
 - 2021-Present **Editorial Board member for “Il Diabete”, an official journal of the Italian Society of Diabetes (SID)**
 - 2020-Present **Associate Editor for Frontiers Clinical Diabetes and Healthcare**
Section of Diabetes Therapies
 - 2017-Present **Associate Editor for BMC Endocrine Disorder**
Section of Epidemiology
 - 2019-Present **Editorial Board member for Frontiers in Endocrinology – Pediatric Endocrinology**

Review Editor

2016-Present **Abstract Reviewer for the American Diabetes Association Scientific Sessions**

76th American Diabetes Association Scientific Sessions, New Orleans, IL, USA

77th American Diabetes Association Scientific Sessions, San Diego, CA, USA

79th American Diabetes Association Scientific Session, San Francisco, CA, USA

- Peer-revision of abstracts submitted for presentation at the Scientific Sessions of the American Diabetes Association

2011-Present **Participation to scientific journals as reviewer for the major international peer-reviewed journals in the field of endocrinology, cardiology and internal medicine**

WORK EXPERIENCE

PAST FELLOWSHIPS

2017-2021 **Senior Research Fellow**

Diabete Trial Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK

[Clinical research](#)

2020-2021 **Post-Doctoral Research Fellowship (Assegno di ricerca cat. B, tipologia 2, SSD MED/13)**

Sapienza University of Rome (Supervisor Prof. Raffaella Buzzetti)

- Definition of the heterogeneity of autoimmune diabetes

[Clinical and translational research](#)

2018-2019 **Post-Doctoral Research Fellowship (Assegno di ricerca cat. B, tipologia 1, SSD MED/13)**

Sapienza University of Rome (Supervisor Prof. Raffaella Buzzetti)

- Bone Biomarkers of cardiovascular risk in T2D and LADA

[Clinical and translational research](#)

2011-2016 **Clinical Fellowship in Endocrinology and Metabolic Diseases**

University Campus Bio Medico, Rome, Italy (Supervisor Prof. Paolo Pozzilli)

- Diabetes
- General endocrinology

[Clinical activity](#)

2014-2015 **Post-Doctoral Research Fellowship in Vascular Cell Biology**

Joslin Diabetes Center, Harvard Medical School (Supervisor Prof. George L. King)

- Vascular complications of diabetes
- Bone disorders in diabetes

[Translational research](#)

2012 **Medical Volunteer**

Centre Medico Chirurgical Saint Damien - Ambanja, Madagascar

- Responsible for the screening of diabetes
- Responsible for the first aid in subjects with acute glycaemic decompensation
- Responsible for the carotid ultrasonography service

[Clinical activity](#)

**WORK EXPERIENCE
COLLABORATION IN
INTERNATIONAL CLINICAL
TRIALS**

- 2020-2022 **Study Investigator** for the International Clinical Trial “ ONWARDS4 - Studio clinico di 26 settimane per confrontare gli effetti e la sicurezza dell’insulina settimanale icodec e dell’insulina giornaliera glargine 100 Unità/mL, entrambe in combinazione con insulina prandiale, con o senza un trattamento antidiabetico non insulinico, in soggetti con diabete di tipo 2 trattati con insulina prandiale e insulina basale.–NN1436-4480”
 EudraCT No.: 2020-000474-16
- Enrolment of study subjects
 - Follow-up visits
 - eCRF filling
- 2020-2022 **Study Investigator** for the International Clinical Trial “ ONWARDS6 - Studio clinico per confrontare l’efficacia e la sicurezza dell’insulina settimanale icodec una volta alla settimana rispetto all’insulina giornaliera degludec 100 Unità/ml una volta al giorno, entrambe in combinazione con insulina aspart, in adulti con diabete di tipo 1 –NN1436-4625”
 EudraCT No.: 2020-002374-27
- Enrolment of study subjects
 - Follow-up visits
 - eCRF filling
- 2021-present **Study Investigator** for the International Clinical Trial “ LDX0319 - Studio di fase 3 multicentrico, randomizzato, controllato in doppio cieco verso placebo volto a valutare l’efficacia e la sicurezza di ladarixin, somministrato per via orale alla dose 400 mg due volte al giorno, in pazienti con diabete di tipo 1 di esordio recente e con ridotta funzionalità β -cellulare.”
 EudraCT No.: 2020-001926-71
- Enrolment of study subjects
 - Follow-up visits
 - eCRF filling
- Clinical research
- 2019- 2021 **Study Investigator** for the International Clinical Trial “ 18B-MC-ITRO A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy (PRONTO-Pump-2)”
 ClinicalTrials.gov Identifier: NCT03830281
- Enrolment of study subjects
 - Follow-up visits
 - eCRF filling
- Clinical research
- 2016-2018 **Study Investigator** for the Phase Ib International Clinical Trial “The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers”
 ClinicalTrials.gov Identifier: NCT02833389
- Enrolment of study subjects
 - Follow-up visits
 - eCRF filling
- Clinical research
- 2010-2017 **Study Coordinator** for the Italy of the International Clinical Trial “ TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk” (before Study Investigator)
 ClinicalTrials.gov Identifier: NCT0017977
- Coordination of the research activities of three Italian centres (Ancona, Palermo and Rome)
 - Follow-up visits of subjects enrolled in Rome
 - Responsible for the study documentation
 - Responsible for the communications with local ethical committees

Clinical research

- 2010-2015 **Study Investigator** for the International Clinical Trial “*BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG-OUTCOME)*”
 ClinicalTrials.gov Identifier: NCT01131676

 - Enrolment of study subjects
 - Follow-up visits
 - eCRF filling
 - Responsible for the study documentation

[Clinical research](#)
- 2012-2016 **Study Investigator** for the International Clinical Trial “*Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus*”
 ClinicalTrials.gov Identifier: NCT01144338

 - Enrolment of study subjects
 - Follow-up visits
 - eCRF filling
 - Responsible for the study documentation

[Clinical research](#)
- 2010-present **Clinical researcher** of the Immunotherapy Diabetes (IMDIAB) group
 Rome, Italy

 - Enrolment of study subjects
 - Statistical analysis
 - Writing committee

[Clinical research](#)

TEACHING ACTIVITIES

- Since academic year 2023/2024 **Member of the teaching body, PhD Course in Molecular Medicine**
 Area of specialty: endocrinology and Diabetes
 Sapienza University of Rome, Italy
[Academy](#)
- Since academic year 2021/2022 **Professor of Endocrinology and Diabetes, Course of Clinical Nursing in specialistic areas.**
 Nurse Degree “N”, Sapienza University of Rome
[Academy](#)
- Since academic year 2021/2022 **Professor of Endocrinology and Diabetes, Course of Integrated pathology,**
 Degree Courses in Medicine and Surgery “A”, “C”, “HT”, Sapienza University of Rome
[Academy](#)
- 2021 and 2022 **New glycemc targets in diabetes**
 II Level Master in Pharmaceutical Department Manager, Camerino University
 2 hour lesson
[Academy](#)
- 2017 **Caveat in diabetes care in the complex patient** (*title of the lesson*)

High Specialty Master in Palliative Care, University Campus Bio Medico, Rome, Italy

- 2.5 hours lesson

[Academy](#)

2015-2016 **Cardiovascular Involvement of Metabolic Disorders** (*title of the lesson*)

Course of Integrated Clinical and Surgical Systemic Pathology, Medicine and Surgery Degree Program, Faculty of Medicine, University Campus Bio Medico, Rome, Italy

- 2 hours lesson

[Academy](#)

2007-2008 and 2008-2009 **Atherogenesis, diabetes and dyslipidemia** (*title of the lesson*)

Course of General Pathology, Dietician Degree Program, Faculty of Medicine, University Campus Bio Medico, Rome, Italy

- 2 lessons, 1 hour each

[Academy](#)

2010-2014 **Medical Student Tutoring (graduate student advisor)**

University Campus Bio-Medico, Rome, Italy

- Teaching activity

[Academy](#)

EDUCATION, TRAINING AND TITLES

2020

Italian National Scientific Qualification as Associate Professor - SSD MED13, SC06/D2 (Endocrinology, Nephrology, Nutrition and Well-being)

March, 2019

Ph.D. Degree (Integrated Biomedical Sciences and Bioethics, curriculum in endocrinology)

University Campus Bio-Medico, Rome - Italy

Degree Thesis: "Adults with autoimmune diabetes: vascular risk, emerging complications and novel disease pathways". Supervisor: Prof. Paolo Pozzilli, University Campus Bio-Medico. Co-supervisor: Prof. Raffaella Buzzetti, Sapienza University of Rome.

July, 2016

Board Certified (Italy) in Endocrinology and Metabolic Diseases.

50 cum laude

University Campus Bio-Medico, Rome - Italy

Degree Thesis (experimental): "Modulation of Osteocalcin Expression in Circulating Monocytes: a New Mechanism of Cardiovascular Disease in Type 1 Diabetes". Supervisor: Prof. Paolo Pozzilli, University Campus Bio-Medico of Rome. Co-Supervisors: Prof. George L King and Prof. Hillary A. Keenan, Harvard Medical School, Boston

November 2015

Advanced Cardiovascular Life Support (ACLS) Provider

Course of the American Heart Association. Wakefield, MA, USA

October 2015

Introduction to Meta-Analysis & Systematic Review Methods, Harvard Catalyst's Biostatistic Program.

Countway Library, Boston, MA, USA

July 8th - 9th 2013

Good Clinical Practice Certificate

Course of the “Società Italiana di Diabetologia”, Rome - Italy
 Skills of Good Clinical Practice

- March, 17th 2013 – March, 23rd 2013 **10th EASD Robert Turner Clinical Research Course**
 European Association for the Study of Diabetes, Oxford – United Kingdom (supervisor: Professor David Matthews)
- Role of clinicians in research
 - Statistics for clinical research in diabetes
 - How to design, plan, and present experiments in clinical research
 - Analysis of results
 - Abstract and paper writing
- March, 21st 2013 **Research Governance and Good Clinical Practice Certificate of Attendance**
 European Association for the Study of Diabetes, Oxford – United Kingdom
- Skills of Good Clinical Practice
- September 2013 **Fellowship in Clinical Medicine**
 Department of Internal Medicine, “Fabrizio Spaziani” Hospital, Frosinone, Italy; Supervisor: Dr Teresa Petricca
- February 2011 **Italian license to practice medicine** 270/270
 University Campus Bio-Medico, Rome - Italy
- July, 22nd 2010 **Degree in Medicine and Surgery** 110 cum laude et mentione
 University Campus Bio-Medico, Rome - Italy
- Degree Thesis (experimental): “*Incidence of type 1 diabetes in Rome and the Lazio region in the 0- to 14-year age-group: a 6-year prospective study (2004-2009)*”. Supervisor: Professor Paolo Pozzilli; Co-supervisor: Dr Silvia Manfrini
- May 2010 **American Heart Association Basic Life Support for Healthcare Providers Certificate**
 American Heart Association, Rome - Italy
- Skills for Basic Life Support
- September 2008 - June 2011 **Internship in Endocrinology and Metabolic diseases**
 Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy. Supervisor: Prof. Paolo Pozzilli
- 2008-2009 **Internship in the Laboratory of Molecular Pathology and Experimental Oncology at the Institute of Neurobiology and Molecular Medicine.**
 Centro Nazionale Ricerche” of Rome. Supervisor: Prof.ssa Emanuela Signori
- 2007-2008 **Clinical Medicine Internship**
 Department of Internal Medicine. University Campus Bio-Medico, Rome, Italy. Supervisor: Prof. Sebastiano Costantino
- 2006 - 2007 **Internship in Human Physiology**
 Laboratory of Neuroscience at University Campus Bio-Medico, Rome, Italy. Supervisor: Prof. Flavio Keller
- July 19th, 2004 **High School Diploma (Classical studies)** 100/100
 “Liceo Classico Glicerio Landriani”. Portici (NA) - Italy

RESEARCH AND CLINICAL SKILLS

- Basic research skills**
- Western-blot
 - RNA extraction by TRIzol from tissues and cell cultures
 - Spin column-based nucleic acid purification from tissues and cell cultures
 - Polymerase Chain Reaction (PCR)
 - Cell cultures: Primary human osteoblast culture; Osteoblast isolation; Osteoblast isolation and cultures from murine long-bones; Culture of human fibroblasts; Culture of human monocytes
 - Isolation of "Peripheral Blood Mononuclear Cells (PBMCs)" from human blood
 - Flow Citometry and Fluorescence Activated Cell Sorting

- Clinical research skills**
- Protocol writing
 - Coordination of study centres in multicentre clinical trials
 - Subject enrolment
 - Study visits
 - eCRF compilation and revision
 - Communication with local ethic committees

- Statistical skills**
- Tests of normality
 - Parametric and non-parametric tests of hypotheses
 - Analysis of Variance and Covariance
 - Higher order linear and logistic regression modeling
 - Multilevel mixed-effects models
 - Log Rank Test
 - Cox Proportional Hazard Models

- Clinical skills**
- **Main fields of clinical activities:** Diabetes; Thyroid disorders; Osteoporosis and other disorders of bone metabolism; Obesity (prevention and treatment); Disorders of lipid metabolism; Secondary hypertension; Cardiometabolic prevention; General endocrinology in adults including pituitary, adrenal and gonadal dysfunction.
 - **Main diagnostic procedures:** Thyroid and parathyroid Doppler-ultrasound; Neck lymph nodes ultrasound; Thyroid fine needle aspiration; Carotid artery Doppler-ultrasound; Lower-limbs arteries Doppler-ultrasound; 24-hours ambulatory blood pressure monitoring (ABPM); Cardiac Autonomic Reflex Tests

PERSONAL SKILLS

Mother tongue(s)

Italian

Other language(s)

English

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

ADDITIONAL INFORMATION

Ongoing Research grants as Principal Investigator or Co-Principal Investigator

Fondo Italiano Scienza (FIS) 2021. Ref Number: FIS_00001148

Title of the project: "Differentiating heart disease between adult-onset autoimmune and type 2 diabetes". Role in the project: Principal Investigator. Mar 2024-Mar 2029

2022 PRIN (Scientific Research Projects of National Interest). Ref number 2022NS7PRM.

Title of the project: "Characterization of overweight/obesity and its relevance in

people with autoimmune diabetes”. Role in the project: Principal Investigator. Oct 2023-Oct 2025

2022 “Sapienza University Progetti Piccoli” Ref number RP1221816784D0A1.

Title of the project: “Impact of obesity on complications of autoimmune diabetes”. Role in the project: PI, Dec 2022 -Dec 2024

Other Ongoing Research grants

2021 “Sapienza University Grandi Attrezzature” grant. Ref number: GA12117A85B76EB4.

Title of the project: “High-parameter spectral cell sorting for the study of inflammation and immunity in metabolic diseases”. Role in the project: Participant (PI: Marcello Arca).

2017 PRIN (Scientific Research Projects of National Interest). Ref number 2017KAM2R5_006.

Title of the project: “Molecular and pathophysiological heterogeneity of autoimmune diabetes: implications for precision medicine”. Role in the project: Co-Investigator. (PI: Raffaella Buzzetti). Aug 2019- Apr 2023

Past research grant as PI or Co-PI

2018 “Italian Ministry of Health, Ricerca Finalizzata for Young Researcher “-Theory Enhancing. Ref number GR-2018-12365982.

Title of the project: “Role of post-translational insulin modifications in the pathogenesis, staging and therapy of type 1 diabetes”. Role in the project: Co-PI, Mar 2019/ Mar 2022.

2019 “Sapienza University Starting Grant – Type II”. Ref number AR21916B3C9E8EF7.

Title of the project: “Correlation between Cardiac Autonomic Neuropathy and Bone Fragility in Autoimmune Diabetes” [Correlazione tra Fragilità Ossea e Neuropatia Autonoma nel Diabete Autoimmune]. Role in the project: Principal Investigator. Nov 2019-Nov 2020.

2017 Grant from the European Foundation for the study of Diabetes (EFSD) for the “EFSD Future Leaders Mentorship Programme for Clinical Diabetologists” Ref number: MS 2017_2

Title of the project: “Improving the assessment of cardiovascular risk in diabetes in the contemporary era”. Role in the project: Principal Investigator. 1 Nov 2017-1 Nov 2020

Other past research grants

2018 “Progetti di Ricerca Sapienza University of Rome”. Title of the project: Genetics and autoantibody heterogeneity of autoimmune diabetes: implications for precision medicine. Role in the project: Co-Investigator. (PI: Raffaella Buzzetti). 2019-2020)

2015 PRIN (Scientific Research Projects of National Interest). Ref number 2015373Z39_001.

Title of the project: “Pancreatic β -cell identity, glucose sensing and the control of insulin secretion”. Role in the project: Co-Investigator. (PI: Paolo Pozzilli). 5 Feb /2017-5 Feb 2020

NIH/NIDDK DiaComp. Ref number: 5 U24 DK076169-10

Title of the project: "Radiographic and proteomic characterization of bone health in patients with type 2 diabetes and type 1 diabetes of extreme duration.". Role in the project: Consultant (PI: Hillary A. Keenan). 1 Oct 2015-30 Sep 2016

2014 "Progetti di Ricerca Sapienza University of Rome". Ref number: C26A147PHW

Title of the project: "Evaluation of microvascular and macrovascular complications in patients with autoimmune diabetes of adults". Role in the project: Co-Investigator.

2014 "Progetto Ateneo Campus Bio-Medico"

Title of the project: "Evaluation of bone strength and WNT pathway in obese patients". Role in the project: Co-investigator

Fondazione Roma "2013 Grant for Biomedical Research: Non communicable Diseases"

Title of the project: "Evaluation of corneal innervation as a new tool to detect autonomic neuropathy in diabetes". Role in the project: Study coordinator.

Honours and Awards

2021 Young Investigator Award of the Italian Society of Endocrinology (SIE) for researchers under the age of 35 (Premio SIE 35).

2020 "Premio Galeno" Young investigator (Under 35) award of the Italian Society of Diabetes (SID)

2019 Young Investigator American Diabetes Association Top Scoring Abstract Award (79th ADA Scientific Sessions), USA

2017 Early Investigator Award of the Endocrine Society, USA

2017 Travel Grant Lilly - Italian Society of Diabetes (SID)

2017 Young Investigator Award of the Italian Society of Endocrinology (SIE).

2017 DiabeteContest Award [diabetecontest.doctor33.it]

2015 Albert Renold Travel Fellowship of the European Foundation for the Study of Diabetes

2014 "Campus Bio-Medico Alumni Association" Award for Research Internationalization

Faculty in National and International meetings and Invited Presentations and Seminars

Year "Title"/Type of presentation/Location

2012 "Therapy of Hypoparathyroidism"/ Grand Rounds / "Sapienza" University of Rome

2013 "Femoral Bone Mineral Density Differs in Female Elderly Obese depending on serum levels of tumor necrosis factor alpha" / Plenary Talk (abstract) / XIII Italian Society of Osteoporosis, Mineral Metabolism and Bone Diseases National Meeting. Bologna, Italy

2014 "In Vivo Corneal Confocal Microscopy: a New non-invasive tool for the study of Cardiac

autonomic Neuropathy in Type 1 Diabetes”/ Plenary talk (abstract) / XXV Italian Diabetes Association Meeting. Bologna, Italy

2014 “From classic type 1 diabetes to NIRAD” /Plenary Talk / XIII Diabetes & Obesity National Meeting. Milan, Italy

2014 “A strange osteoporosis. Interactive clinical case” / Plenary talk / Update in Bone Metabolism meeting. Rome, Italy

2014 “Screening the epidemic of diabetes” /Plenary talk/ Diabetes and thyroid disorders in clinical practice today: progresses and challenges. Rome, Italy

2015 “Diabetes and heart rate control dysfunction (Cardiac Autonomic Neuropathy)/ Plenary Talk/ 2015 Latin American conference on cardiometabolic diseases management, Huatulco, Mexico

2015 “Statin and Diabetes”/ Plenary Talk/ 2015 Latin American conference on cardiometabolic diseases management, Huatulco, Mexico

2015 “Bone Fragility in Diabetes. Insights from the 50-Year Joslin Medalist Study”/ Plenary Talk/ Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA

2016 “Evaluation of Bone Frailty in Diabetes” / Plenary Talk/ Cassino, Italy

2016 “Drugs interfering with Levo-Thyroxine therapy” / Plenary Talk / “Università Campus Bio-Medico”, Italy

2016 “Evaluation of fracture risk in diabetes” / Plenary talk / III International Symposium on Bone and Diabetes. Cassino, Italy

2016 “Relationship between sclerostin, bone turnover and metabolic syndrome in patients with type 2 diabetes and LADA” / Plenary talk (abstract) / XXVI Italian Diabetes Association Meeting. Rimini, Italy

2016 “Bone frailty and quality in elderly subjects with >50 years of type 1 diabetes duration” // Plenary talk (abstract) / XXVI Italian Diabetes Association Meeting. Rimini, Italy.

2016 “Age and LDL cholesterol differentially affect bone quality in subjects with extreme duration type 1 diabetes” / Plenary talk (abstract) / The Endocrine Society’s 98th annual meeting & Expo. Boston, MA, USA

2016 “Algorithms for personalized medicine in diabetes” /Workshop /2016 Diabetes and Thyroid diseases management: clinical features and management, Lisboa, Portugal

2016 “High Density Lipoprotein Modulates Osteocalcin Expression in Circulating Monocytes: A Potential Marker of CVD in Type 1 Diabetes” / Edwin Bierman Award Lecture Session (abstract)/ 76th Scientific Session American Diabetes Association. New Orleans, LA, USA

2016 “Diabetes Management: how to choose the right drug?” / Plenary talk / 2016 Latin American conference on cardiometabolic diseases management, Sao Paulo, Brasil.

2017 “Latent Autoimmune Diabetes of Adulthood” / Plenary Talk / 5th Middle East Diabetes Conference, MedLab 2017, Dubai, United Arab Emirates

2017 “Diabetes ketoacidosis: is the picture changing?” / Plenary Talk / 21st Pan Arab Conference on Diabetes, Cairo, Egypt

2017 “C-peptide: biology and clinical relevance?” /Workshop / 21st Pan Arab Conference on Diabetes, Cairo, Egypt

2017 Faculty / II Update in Endocrinology and Metabolism in Andrology / Cassino, Rome, Italy.

- 2017 “ADA Standards of Care 2017” / Plenary talk / DATE8 meeting, Milan, Italy
- 2017 “Frail patient with type 2 diabetes” / Interactive clinical case / Evolving strategies to tackle diabetes and thyroid disorders, Milan, Italy
- 2017 “PRO-CON Debate: which should be the first choice? GLP1-RA vs Insulin” / 43th National Meeting of the Romanian Society of Diabetes, Nutrition and Metabolism, Brasov, Romania
- 2017 “Morbid Obesity” / Interactive Clinical Case / 2017 Hot topics in cardiometabolism: an interactive update, Bogotá, Colombia.
- 2017 “Old and New Perspective on Cardiac Autonomic Neuropathy” / Satellite symposium “From the cornea to the heart” / 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal.
- 2017 “Glucose control in diabetic patients: is it relevant for cardiovascular diseases? Cons” / Invited lecture – debate format / Diabetes, heart and kidney, Rome, Italy.
- 2017 “The bone-vascular axis: insights from adults with autoimmune diabetes” / Grand Round/ Seminar Series, Oxford Centre for Diabetes Endocrinology and Metabolism, university of Oxford, UK.
- 2017 “Controversies in type 2 diabetes management” (7 lectures 1 hour each) / Diabetes Gulf Tour / Dubai&Abu Dhabi, UAE – Muscat, Oman – Doha, Qatar – Salmiya, Kuwait, 24-29 November, 2017.
- 2018 “Patient at increased risk of nephropathy: new evidences with SGLT2i” / Plenary Talk / Update in metabolic disorders, 3rd edition / Cassino, Italy
- 2018 “Implications of the new glucose-lowering drugs in patients with erectile dysfunction” / Plenary Talk / Update in metabolic disorders, 3rd edition / Cassino, Italy
- 2018 “Hospital Management of Diabetes” / Invited lecture / Medical Surgery International Conference of Diabetes and Diabetes / Algeri 19-22 April 2018
- 2018 “New Insulins” / Invited lecture / Medical Surgery International Conference of Diabetes and Diabetes / Algeri 19-22 April 2018
- 2018 “Complications of Autoimmune Diabetes in adults and aging people” / Grand Round / Clinical Seminary Series/ University of Ferrara, Italy
- 2018 “Insulin and SGLT2i therapy for type 1 diabetes” / Plenary talk / 44th National Congress of Romanian Society of Diabetes, Nutrition and Metabolic Diseases, Brasov, Romania
- 2018 “The management of the diabetic patient along with best practices, new developments and the ideal devices for a better compliance” / 2h Workshop / PIKDARE, Como, Italy
- 2019 “Complications: what do we know in autoimmune diabetes?” / Plenary talk / Rome, Italy
- 2019 “Latent Autoimmune Diabetes in Adults” / Plenary talk / 5th Diabetes Conference – Arab Health 2019 / Dubai, UAE
- 2019 “Vascular Complications in LADA similar or different from T2D: More Macroangiopathy” / Plenary Talk / 7th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy) / Sorrento, Italy
- 2019 “Should we consider metabolic bariatric surgery at the early diagnosis of diabetes? No” / Plenary Talk / 7th World Congress on Controversies to Consensus in Diabetes Obesity and Hypertension (CODHy) / Sorrento, Italy
- 2019 “Benefits of stratification of adult-onset diabetes” / Plenary talk / The 25th Bart’s International Symposium / St. Bartholomew’s Hospital, London, UK.

2019 “Changing therapeutic algorithm of type 2 diabetes: an update on national and international guidelines” / Plenary Talk/ Focus Group 2.0 / Sapienza University of Rome, Italy

2019 “GLP1-RA & SGLT2i: rationale of novel therapies in diabetes” / Plenary Talk/ Focus Group 2.0 / Sapienza University of Rome, Italy

2019 “Microvascular Complications in Latent Autoimmune Diabetes of Adults: Results from the UKPDS / Plenary Talk (abstract) /79th Scientific Session American Diabetes Association. San Francisco, CA, USA

2019 “Risk of microvascular complications over 30 years in latent autoimmune diabetes of adults compared with type 2 diabetes / Plenary Talk (abstract) / 55th Annual meeting of the European Association for the Study of Diabetes, Barcelona, Spain

2020 “Diabete autoimmune dell’adulto: eterogeneità clinica e rischio di complicanze” /Plenary Talk/ Parma Diabete/ Parma, Italy

2020 “Libreview e la gestione del paziente da remoto”/ Webinar Libreview/ Italy

2020 “Percorso interattivo Diabete e Rischio Cardiovascolare” / Webinar Di@binar, dialoghi online sull’utilizzo dei GLP1 agonisti nel diabete tipo 2, Italy

2020 Chair of Poster Session “Islets and Antibodies in type 1 diabetes” during the 56th virtual EASD Annual Meeting

2020 “Quando utilizzare i nuovi farmaci antidiabetici: solo nei pazienti ad alto rischio cardiovascolare” / Debate (Webinar)/ XV National Meeting of the ATBV (Atherosclerosis, Thrombosis and Vascular Biology) Study Group, Novara, Italy

2020 “Nuovi paradigmi terapeutici e organizzativi nel trattamento del paziente con diabete tipo 2”/ Webinar Cooperation FAD/ Rome, Italy

2020 “Predictors of adipose tissue dysfunction and cardiovascular risk in obesity”/ Virtual Plenary Talk/ 46th Annual (Virtual) Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD)

2020 “GLP-1 analogs-SGLT2 inhibitors nei diabetici di tipo 2: La prevenzione della malattia renale” / Webinar Update in malattie del metabolismo / Italy

2020 “Insulin administration techniques: which methodology and consequences of malpractice”/ Webinar MDT Diabetes Workshop 2020/International

2020 “Glycemic targets: an update”/ Webinar MDT Diabetes Workshop 2020/International

2020 “Covid-19 and diabetes: real world data about the interaction of two pandemics” / Webinar MDT Diabetes Workshop 2020/International

2020 “Secrezione insulinica: come quando e a chi misurarla”/ Plenary Talk / Congresso Regionale SID-AMD Lazio 2020, Rome, Italy

2020 “Diagnosis and management of LADA”/ Virtual Plenary Talk / Endocrine e-Dialogues, a web-based program of the Society for Promotion of Education in Endocrinology & Diabetes (SPEED), India

2020 “Gestione terapeutica del diabete mellito tipo 1 nell’età di transizione e nel giovane adulto/Webinar/ 3rd TALENT (Transition and AdoLescents ENdocrine disease managment) Study Group meeting, Rome, Italy

2020 “Le relazioni pericolose tra diabete e rene nella pratica clinica”/ Workshop, Webinar MultiDiab, Rome, Italy

- 2020 “Terapia di associazione all’insulina nel diabete tipo 1: SGLT2i” / Virtual Plenary Talk/ 28° Congresso nazionale della Società Italiana di Diabetologia (SID), Italy
- 2021 “Ipoglicemie severe: trattamento innovativo con glucagone spray nasale”/ Virtual Plenary Talk/ Webinar SID-AMD Regione Lazio – Il diabete nell’era del Covid-19: è tempo di domande.
- 2021 “Declino Cognitivo nel diabete tipo 2, quali evidenze?”/ Virtual Plenary Talk / Web Series “Il Diabete tipo 2 degli anni ’20, cosa ci aspetta nel decennio post-pandemia” – Webinar 2: “la nuova era delle complicanze non classiche del diabete tipo 2”.
- 2021 “Fragilità ossea nel diabete tipo 2, quali evidenze?”/ Virtual Plenary Talk / Web Series “Il Diabete tipo 2 degli anni ’20, cosa ci aspetta nel decennio post-pandemia” – Webinar 2: “la nuova era delle complicanze non classiche del diabete tipo 2”.
- 2021 “New Perspectives in Chronic Complications of Autoimmune Diabetes”/ Plenary Talk/41st National Meeting of the Italian Society of Endocrinology (SIE), Rome, Italy
- 2021 “EFSD Future Leaders Mentorship Programme for Clinical Diabetologists: Improving the assessment of Cardiovascular Risk in Diabetes in the Contemporary Era”/ Virtual Talk/ 57th Annual Meeting of the EASD
- 2021 “Autoimmune diabetes in adults and micro- and macro-complications of diabetes”/ Virtual talk/ 35th Meeting of the Italian Society for the Study of Atherosclerosis
- 2021 “Precision Medicine in Diabetes: clinical applications of precision medicine” / Plenary Talk/ Interdisciplinary Forum of the Italian Society of Diabetes (SID) Panorama Diabete/ Riccione, Italy
- 2022 “Quando preferiamo cominciare con l’insulina basale, quando invece con il GLP1-RA, e quando magari con tutti e due insieme”/ Plenary Talk / XVIII corso nazionale di alta formazione in diabetologia “La terapia del diabete mellito a cento anni dalla scoperta dell’insulina”, Perugia University/ Perugia, Italy
- 2022 “Covid-19 vaccine in people with diabetes: safe and effective?” /Plenary Talk / Endo2022, annual meeting of the Endocrine Society/ Atlanta, USA/ Jun 022
- 2022 “ Risk of vascular complications in autoimmune diabetes” / Plenary Talk / CIVIS Webinar “Advancing knowledge about the heterogeneity of diabetic cardiomyopathy/ Online/ 8 July 2022
- 2022 “Combination therapy with SGLT2i and GLP1-RA: a clinical case” / Plenary Talk / Incontri Italiani di Endocrinologia e Metabolismo della SIE 2022 / Naples, Italy.
- 2022 “Benefits of gliflozins: new horizons. In Type 1 diabetes” . / Plenary Talk/ 29th National Meeting of the Italian Society of Endocrinology/ 27th October 2022/ Rimini, Italy
- 2022 “Antiplatelet and anticoagulant therapy in type 2 diabetes” / Plenary Talk / Italian Society of Internal Medicine meeting “Type 2 Diabetes in internal medicine” / Decemebr 2022 / Rome, Italy.
- 2022 “Diabetes and cognitive impairment” /Plenary Talk/ International Diabetes Federation (IDF) meeting 2022/ December 2022 / Lisbon, Portugal
- 2022 “Platelet effects of anti-diabetes drugs – HF and diabetes therapy” /Plenary Talk/ Dimensions in Diabetes The Endocrine Society’s 8th Annual Program /Mumbai, India, 15th-16th October 2022
2023. “Le nuove linee guida ISS (2023) per la terapia del DM2 e la nota 100 AIFA” / Plenary Talk/ “Identificazione Pazienti DM2 a rischio, con danno cardiorenale e appropriato utilizzo di SGLT2 Dall’AUDIT CLINICO alla COMPETENZA CERTIFICATA” – SIMG (Società Italiana di Medicina Generale e delle Cure Primarie) College / Rome, Italy, 10 June 2023
2023. “Protezione cardiorenale nel paziente diabetico tipo 2: dalle evidenze alla pratica clinica” / Plenary

Talk/ "Identificazione Pazienti DM2 a rischio, con danno cardiorenale e appropriato utilizzo di SGLT2 Dall'AUDIT CLINICO alla COMPETENZA CERTIFICATA" –SIMG (Società Italiana di Medicina Generale e delle Cure Primarie) College / Rome, Italy, 10 June 2023

2023. Chair of the short oral session "Refining and redefining insulin therapy in type 1 diabetes" at the 59th EASD Annual Meeting, Hamburg, Germany, 02 - 06 September 2023

2023. "Diabetic neuropathy". SID Academy 2023, Rome, Italy, 7 Oct 2023

2023 "Strategies of cardiovascular risk stratification" / Plenary talk/ SID, SISA, AMD meeting on "New frontiers of hypolipemic therapy"/ Rome, Italy, 7 Oct 2023.

2023 Faculty at the 6^o Cardionefrologia meeting of the Società Italiana di Nefrologia, 25-25 October 2023/ Session: LA GESTIONE DELLA MALATTIA RENALE DIABETICA OVVERO NON DIABETICA ALLA LUCE DELLE NUOVE INDICAZIONI TERAPEUTICHE".

2023 "Impact of the new anti-diabetes therapies on male hypogonadism" / Plenary Talk /Giornate Romane di Andrologia / Rome, 17 Oct 2023

Memberships

- 2022- Present Member of the Scientific committee of the Italian Society of Diabetes (SID)
- 2020- Present. Member of the scientific committee (commissione didattica) of the Italian Society of Endocrinology (SIE)
- 2016- Present. Member of YoSID (Youngest of the Italian Society of Diabetes)
- 2016- Present. Member of the scientific committee of YoSID group
- 2015 – Present. Member of "Associazione Medici Endocrinologi"
- 2013 – Present. Member of "The Endocrine Society"
- 2013 – Present. Member of the "Italian Society of Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)"
- 2011 – Present. Member of the "European Association for the Study of Diabetes (EASD)"
- 2011 – Present. Member of the "Italian Society of Endocrinology (SIE)"
- 2011 – Present. Member of the "Italian Society of Diabetes (SID)".

PUBLICATIONS

A full list of publications on pubmed is available at :

<https://www.ncbi.nlm.nih.gov/myncbi/1xGOuoCbV1uAs/bibliography/public/>

Full papers

1. C. Bizzarri, R. M. Pinto, D. Pitocco, E. Astorri, M. Cappa, M. Hawa, G. Giannone, A. Palermo, **E. Maddaloni**, D. R. G. Leslie, and P. Pozzilli, "Diabetes-related autoantibodies in children with acute lymphoblastic leukemia." *Diabetes Care*, vol. 35, no. 3, p. e23, Mar 2012. IF: 16.019
2. A. Palermo, **E. Maddaloni**, and P. Pozzilli, "Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?," *Expert Opinion on Biological Therapy*, vol. 12, no. 6, pp. 767–72, Jun 2012. IF: 3.224
3. **Maddaloni E**, Del Toro R, Khazrai MY, Lauria A, Palermo A, Briganti SI, Rizza W, Coppola G, Pozzilli P. [A metabolic challenge when rowing. The importance of basal glucose before exercise: an experience with sportsmen of the club Aniene]. *Sport&Medicina*. Luglio-Agosto 2012, 4 - Article in Italian. IF: 0
4. N. Napoli, R. Strollo, D. Pitocco, C. Bizzarri, **E. Maddaloni**, D. Maggi, S. Manfrini, A. Schwartz, and P. Pozzilli, "Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes." *PLoS One*, vol. 8, no. 2, p. e56488, Jan 2013. IF 2.740
5. Y. M. Khazrai, **E. Maddaloni**, M. Altomare, F. Cacciapaglia, and P. Pozzilli, "New technologies aiding dietary programmes for weight control: the oral glucose spray.," *Endocrine*, vol. 45, no. 2, pp. 288-292, Mar 2014. IF: 3.235

6. **E. Maddaloni**, P. Pozzilli, "Comment on: "Early insulin treatment in type 2 diabetes: ORIGINAL sin or valuable choice as ORIGINAL treatment? An open debate on the ORIGIN study results". *Nutrition Metabolism and Cardiovascular Disease*, vol. 24, no. 1, p. e1 Jan 2014. [IF: 3.700](#)
7. **E. Maddaloni**, P. Pozzilli, "SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes)". *Endocrine*, vol. 46, no. 1, pp 3-5, May 2014. [IF 3.235](#)
8. **E. Maddaloni**, G. Capolupo, A. Palermo, S. Manfrini, FM Di Matteo, RF Grasso, R. Coppola, P. Pozzilli. " Continuous glucose monitoring and robot surgery of an insulinoma: a case report and review of the literature". *Pancreas*, vol. 43, no. 3, pp 483-485, Apr. 2014. [IF: 2.675](#)
9. **E. Maddaloni**, P. Pozzilli. "Will we ever cure diabetes?". *Diabetes Management*, vol. 4, no. 3, pp. 219-221, May 2014. [IF: 0](#)
10. **E. Maddaloni**, L. D'Onofrio, A. Lauria, AR Maurizi, R. Strollo, A. Palermo, N. Napoli, S. Angeletti, P. Pozzilli, S. Manfrini. "Osteocalcin levels are inversely associated with Hba1c and BMI in adult subjects with long-standing type 1 diabetes". *J Endocrinol Invest*, vol. 37, no. 7, pp 661-666. Jul 2014. DOI: 10.1007/s40618-014-0092-7, PMID: 24859912. [IF: 3.439](#)
11. N. Napoli, R. Strollo, D. Sprini, **E. Maddaloni**, GB Rini, E. Carmina. Serum 25-OH Vitamin D in relation to Bone Mineral Density and Bone Turnover. *Int J Endocrinol*. 2014;2014:487463. doi: 10.1155/2014/487463. [Epub 2014 Jul 7]. [IF: 2.287](#)
12. A. Palermo, R. Strollo, R. Papalia, L. D'Onofrio, **E. Maddaloni**, SI Briganti, N. Napoli, U. Vespasiani, S. Costantino, P. Pozzilli, V. Denaro, S. Manfrini. "Severe Hypophosphatemic Osteomalacia Secondary to Fanconi Syndrome Due to Adefovir: A Case Report". *Endocr Pract*. Vol. 20, no. 12, pp e246-249. December 2014 [IF: 4.149](#)
13. **E. Maddaloni**, P. Pozzilli. "Getting it right for people with LADA". *Diabetes Voice*. Vol 59, no. 3, pp 31 – 32. September 2014. [IF: 0](#)
14. **E. Maddaloni**, P. Pozzilli. "What future for personalized strategies to cure diabetes". *Treatment strategies - Diabetes*. Vol. 6, no. 1, 2014. [IF: 0](#)
15. **E. Maddaloni**, F. Sabatino, R. Del Toro, S. Crugliano, S. Grande, A. Lauria Pantano, AR Maurizi, A. Palermo, S. Bonini, P. Pozzilli, S. Manfrini. "In vivo corneal confocal microscopy as a novel non-invasive tool to investigate cardiac autonomic neuropathy in Type 1 diabetes." *Diabet Med*. Vol. 32, no 2, pp 262-266. Feb 2015. PMID: 25251450 [doi: 10.1111/dme.12583] [IF: 3.107](#)
16. A. Palermo, R. Strollo, **E. Maddaloni**, D. Tuccinardi, L. D'Onofrio, SI Briganti, G. Defeudis, M. De Pascalis, M.C. Lazzaro, G. Colleluori, S. Manfrini, P. Pozzilli, N. Napoli. "Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity." *Clin Endocrinol (Oxf)*. Vol. 82, no 4, pp 615-619. Apr 2015 [doi: 10.1111/cen.12672]. [IF: 2.897](#)
17. P. Pozzilli, **E. Maddaloni**, R. Buzzetti. "Combination immunotherapies for type 1 diabetes mellitus". *Nat Rev Endocrinol*. Vol. 11, no. 5, pp 289-297. May 2015. [IF: 24.646](#)
18. A. Santonati, P. Palermo, **E. Maddaloni**, D. Bosco, A. Spada, F. Grimaldi, B. Raggiunti, R. Volpe, S. Manfrini, F. Vescini, Hypoparathyroidism AME group. "PTH(1-34) for surgical hypoparathyroidism: a prospective open label investigation of efficacy and quality of life". *J Clin Endocrinol Metab*. Vol. 100, no. 9, pp. 3590-7 Sep 2015. PMID: 26196949. [IF: 5.605](#)
19. R. Cesareo, M. Iozzino, L. D'Onofrio, I. Terrinoni, **E. Maddaloni**, A. Casini, G. Campagna, A. Santonati, A. Palermo. "Effectiveness and safety of calcium and vitamin D treatment for postmenopausal osteoporosis". *Minerva Endocrinol*. Vol. 40, no. 3, pp. 231-237. Jul 2015. PMID: 26205648. [IF: 1.817](#).
20. A. Nusca, A. Lauria Pantano, R. Melfi, C. Proscia, **E. Maddaloni**, R. Contuzzi, F. Mangiacapra, A. Palermo, S. Manfrini, P. Pozzilli, G. Di Sciascio. "Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study". *J Diabetes Res*. Vol. 2015, Article ID 250201, 11 pages, Jul 2015. doi:10.1155/2015/250201. [IF: 3.040](#)

21. M. Musumeci, A. Palermo, L. D'Onofrio, G. Vadalà, V. Greto, E. Di Stasio, **E. Maddaloni**, M. Di Rosa, D. Tibullo, A. Silvia, N. Napoli, V. Denaro, S. Manfrini. "Serum Chitotriosidase in postmenopausal women with severe osteoporosis." *Osteoporos Int*. Vol. 27, no 2, pp: 711-716, Feb 2016 doi: 10.1007/s00198-015-3254-3. PMID: 26243359. IF: 3.819
22. **E. Maddaloni**, N Lessan, A. Al Tikriti, R. Buzzetti, P.Pozzilli, MT Barakat. "Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin- Requirement." *Plos One*. Vol. 10, no 8, pp: e0131837, eCollection 2015. PMID: 26252955. Doi: 10.1371/journal.pone.0131837 IF: 2.776
23. **E. Maddaloni**, L. D'Onofrio, P. Pozzilli. "Frailty and Geography: should these two factors be added to the ABCDE contemporary guide to diabetes therapy?". *Diabetes Metab Res Rev*. Vol. 32, no 2, pp 169-75. Feb 2016. doi: 10.1002/dmrr.2762. PMID: 26484614. IF: 4.758
24. K. Park, A. Mima, Q. Li, C. Rask-Madsen, P. He, K. Mizutani, S. Katagiri, Y. Maeda, IH. Wu, M. Khamaisi, S.R. Preil, **E. Maddaloni**, D. Sørensen, L.M. Rasmussen, P.L. Huang, G.L. King. "Insulin decreases atherosclerosis by inducing endothelin receptor B expression". *JCI Insight*. Vol 1, no. 6, pii: e86574. May 2016. PMID: 27200419. IF: 6.014
25. **Maddaloni E**, Pozzilli P. "Why China guidelines for type 2 diabetes represent an opportunity for treating this disease". *Diabetes Metab Res Rev* Vol. 32, no. 5, pp: 438-439. Jul 2016. doi: 10.1002/dmrr.2825. PMID: 27464263. IF: 4.758
26. **Maddaloni E**, Cavallari I, De Pascalis M, Keenan H, Park K, Manfrini S, Buzzetti R, Patti G, Di Sciascio G, Pozzilli P. "Relation of Body Circumferences to Cardiometabolic Disease in Overweight-Obese subjects". *Am J Cardiol*. Vol. 118, no. 6, pp: 822-827. Jun 2016 doi: 10.1016/j.amjcard.2016.06.044. PMID: 27457430 IF: 2.843
27. **Maddaloni E**, Sabatino F. "In vivo corneal confocal microscopy in diabetes: Where we are and where we can get." *World J Diabetes*. Vol. 7, no.17 pp: 406-41. Sep 2016. doi: 10.4239/wjd.v7.i17.406. PMID: 27660697 IF: 0
28. Keenan HA, **Maddaloni E**. "Bone Microarchitecture in Type 1 Diabetes: It Is Complicated." *Curr Osteoporos Rep*. Vol. 14, no. 6, pp: 351-358, December 2016. doi: 10.1007/s11914-016-0338-8. PMID: 2770439 IF: 3.927
29. Soare A, Khazrai MY, Fontana L, Del Toro R, Lazzaro MC, Di Rosa C, Buldo A, Fioriti E, **Maddaloni E**, Angeletti S, Di Mauro A, Gesuita R, Skrami E, Tuccinardi D, Fallucca S, Pianesi M, Pozzilli P. "Treatment of reactive hypoglycemia with the macrobiotic Ma-pi 2 diet as assessed by continuous glucose monitoring: The MAHYP randomized crossover trial." *Metabolism*. Vol. 69, pp: 148-156. Apr 2017. doi: 10.1016/j.metabol.2017.01.023, PMID 28285645. IF: 6.513
30. **Maddaloni E**, D'Eon S, Hastings S, Tinsley LJ, Napoli N, Khamaisi M, Bouxsein ML, Fouda SMR, Keenan HA. "Bone health in subjects with type 1 diabetes for more than 50 years." *Acta Diabetol*. Vol. 54, no. 5, pp: 479-488. May 2017 doi: 10.1007/s00592-017-0973-2; PMID: 28236093. IF 2.996
31. Buzzetti R, Zampetti S, **Maddaloni E**. "Adult-onset autoimmune diabetes: current knowledge and implication for management." *Nat Rev Endocrinol*. Vol. 13, no 11, pp: 674-686. Nov 2017 Doi: 10.1038/nrendo.2017.99; PMID: 28885622. IF: 24.646
32. **Maddaloni E**, Pastore G, Del Buono MG, Porcari A, Fittipaldi M, Garilli F, Tiberti C, Angeletti S, Pozzilli P, Mottini G, Napoli N. "High prevalence of autoimmune diabetes and poor glycaemic control among adults in Madagascar: a brief report from a humanitarian health campaign in Ambanja." *J Diabetes Res*. 2017; 3860674. Epub Sep 2017. doi: 10.1155/2017/3860674. IF: 3.040
33. **Maddaloni E**, Xia Y, Park K, D'Eon S, Tinsley LJ, St-Louis R, Khamaisi M, LI Q, King GL, Keenan HA. "High Density Lipoprotein modulates osteocalcin expression in circulating monocytes: a potential protective mechanism for cardiovascular disease in type 1 diabetes." *Cardiovasc Diabetol*. Vol. 16, no. 1 pp:116. Sep 2017. doi: 10.1186/s12933-017-0599-2. PMID

28915881. [IF: 5.948](#)

34. **Maddaloni E**, Pozzilli P. "Diabetes: the disease of the 10D." *Endocrine*. Vol. 61, no. 2, pp. 353-354. Aug 2018. doi: 10.1007/s12020-017-1454-7 PMID: 29075975. [IF: 3.296](#)
35. Park K, Li Q, Evcimen ND, Rask-Madsen C, Maeda Y, **Maddaloni E**, Yokomizo H, Shinjo T, St-Louis R, Fu J, Gordin D, Khamaisi M, Pober D, Keenan H, King GL. "Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function." *Arterioscler Thromb Vasc Biol*. Vol. 38, no.1, pp: 92-101, Jan 2018. doi: 10.1161/ATVBAHA.117.310291. PMID: 29162603. [IF: 6.618](#)
36. **Maddaloni E**, Cavallari I, Napoli N, Conte C. "Vitamin D and Diabetes Mellitus." *Front Horm Res*. vol. 50, pp: 161-176. Mar 2018 doi: 10.1159/000486083. PMID: 29597238. [IF: 0](#)
37. Lauria A, **Maddaloni E** (first author equal contribution), Briganti SI, Beretta Anguissola G, Perrella E, Taffon C, Palermo A, Pozzilli P, Manfrini S, Crescenzi A. "Differences between ATA, AACE/ACE/AME and ACR TI-RADS ultrasound classifications performance in identifying cytological high-risk thyroid nodules." *Eur J Endocrinol*. Vol. 178, no. 6, pp: 595-603. Jun 2018. doi: 10.1530/EJE-18-0083. PMID: 29626008. [IF: 5.107](#)
38. **Maddaloni E**, Buzzetti R. "Why only macro and not micro in type 2 diabetes? Time to change the goals of clinical trials in diabetes." *Diabetes Metab Res Rev*. Vol. 34, no. 6, pp: e3012. Sep 2018. doi: 10.1002/dmrr.3012. PMID: 29673094. [IF: 4.758](#)
39. Peralice S, Vigevano F, Del Toro R, Napoli N, **Maddaloni E**. "Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis." *Curr Diab Rep*. Vol. 18, no. 10, pp: 84. Aug 2018. doi: 10.1007/s11892-018-1060-y. PMID: 30121859. [IF: 3.996](#)
40. Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, **Maddaloni E**, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. "Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs." *Nat Rev Cardiol*. Vol 16, no. 2, pp: 113-130. Feb 2019. doi: 10.1038/s41569-018-0080-2. PMID: 30250166. [IF: 17.420](#)
41. **Maddaloni E**. "New strategy to study the impact of ethnicity on diabetic neuropathy." *Diabetes Metab Res Rev*. Vol. 35, no. 1, pp: e3080. Jan 2019. doi: 10.1002/dmrr.3080. PMID: 30261130. [IF: 4.758](#)
42. Cavallari I, Delli Veneri A, **Maddaloni E**, Melfi R, Patti G, Napoli N, Pozzilli P, Di Sciascio G. "Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes." *Curr Diab Rep* Vol. 18, n. 12, pp: 138. Oct 2018. doi: 10.1007/s11892-018-1117-y. PMID: 30370486. [IF: 3.996](#)
43. Cavallari I, **Maddaloni E**. "Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand." *Diabetes Metab Res Rev*. Vol. 35, n. 4, pp: e3124. May 2019 doi: 10.1002/dmrr.3124; PMID: 30604504. [IF: 4.758](#)
44. Strollo R, Vinci C, Napoli N, Fioriti E, **Maddaloni E**, Åkerman L, Casas R, Pozzilli P, Ludvigsson J, Nissim A. "Antibodies to oxidized insulin improve prediction of type 1 diabetes in children with positive standard islet-autoantibodies." *Diabetes Metab Res Rev*. Vol. 35, n. 4, pp: e3132. May 2019. doi: 10.1002/dmrr.3132. PMID: 30693639. [IF: 4.758](#)
45. Ho HCH, **Maddaloni E**, Buzzetti R. "Risk Factors and Predictive Biomarkers of Early Cardiovascular Disease in Obese Youth." *Diabetes Metab Res Rev*. Vol. 35, n. 4, pp: e3134. May 2019. doi: 10.1002/dmrr.3134. PMID: 30706683. [IF: 4.758](#)
46. Peralice S, Vari R, Minutolo A, Maurizi AR, Fioriti E, Napoli N, Pozzilli P, Manfrini S, **Maddaloni E**. "Biomarkers of response to alpha-lipoic acid:palmitoyletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy." *Endocrine* Vol. 66, n. 2, pp: 178-184. Nov. 2019 doi: 10.1007/s12020-019-01917-w; PMID: 3094991. [IF: 3.296](#)
47. Leanza G, **Maddaloni E** (first author equal contribution), Pitocco D, Conte C, Palermo A, Maurizi AR, Pantano AL, Suraci C, Altomare M, Strollo R, Manfrini S, Pozzilli P, Schwartz AV,

- Napoli N. "Risk factors for fragility fractures in type 1 diabetes." *Bone*. Vol. 125, pp: 194-199. Aug 2019. doi: 10.1016/j.bone.2019.04.017. PMID: 31059862 [IF: 4.360](#)
48. **Maddaloni E**, Coleman RL, Pozzilli P, Holman RR. "Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85)." *Diabetes Obes Metab* 2019. Vol 21, n.6, pp: 2115-2122. doi: 10.1111/dom.13788. PMID: 31099472. [IF: 6.133](#)
49. Luordi C, **Maddaloni E**, Bizzarri C, Pedicelli S, Zampetti S, D'Onofrio L, Moretti C, Cappa M, Buzzetti R. "Wrist circumference is a biomarker of adipose tissue dysfunction and cardiovascular risk in children with obesity." *J Endocrinol Invest*. 2019. doi: 10.1007/s40618-019-01086-7; PMID: 31347024. [Epub ahead of print]. [IF: 3.439](#)
50. Leanza G, **Maddaloni E**, Schwartz A, Napoli N. "Response to: Letter to editor in response to article published by Leanza et al." *Bone*. Vol. 127, pp: 675. Oct 2019. doi: 10.1016/j.bone.2019.06.028. PMID: 31445665 [IF: 4.360](#)
51. **Maddaloni E**, Bellizzi E, Buzzetti R. "Obiettivi e rischi della terapia del diabete nell'anziano." [Goals and risks of diabetes therapy in the elderly – Article in Italian]. *L'Endocrinologo* 2019. Vol. 20, pp: 266-271. DOI: 10.1007/s40619-019-00619-9
52. D'Onofrio L, **Maddaloni E**, Buzzetti R. "Osteocalcin and sclerostin: Background characters or main actors in cardiovascular disease?" *Diabetes Metab Res Rev*. Vol. 36, n. 1, pp: e3217. Jan 2020 DOI: 10.1002/dmrr.3217. PMID: 31600861
53. **Maddaloni E**, Coleman RL, Agbaje O, Buzzetti R, Holman RR. "Time-varying Risk of Microvascular Complications in Latent Autoimmune Diabetes of Adulthood Compared with Type 2 Diabetes in Adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)". *The Lancet. Diabetes & Endocrinology*. Vol. 8, n. 3, pp: 206-215. Mar 2020. DOI: 10.1016/S2213-8587(20)30003-6. PMID: 32032540.
54. **Maddaloni E**, Buzzetti R. "Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics." *Diabetes Metab Res Rev*. Vol.36, n. 7, pp:33213321. Oct 2020. DOI: 10.1002/dmrr.3321. PMID: 32233018
55. Pieralice S, Zampetti S, **Maddaloni E**, Buzzetti R. "“H” for Heterogeneity in the Algorithm for Type 2 Diabetes Management". *Curr Diab Rep*. Vol. 20, n. 5, pp:14. May 2020. DOI: 10.1007/s11892-020-01297-w. PMID: 32198647
56. **Maddaloni E.**, Mignogna C., Coraggio L., Di Guida M., Buzzetti R. "Bone-related markers of cardiovascular disease." *European Medical Journal*. Vol. 5, n. 2, pp:54-62, June 2020.
57. **Maddaloni E**, Moretti C, Mignogna C, Buzzetti R. "Adult onset autoimmune diabetes in 2020: an update." *Maturitas* Vol. 137, pp: 37-44. Jul 2020. DOI: 10.1016/j.maturitas.2020.04.014. PMID: 32498935
58. **Maddaloni E**, Coraggio L, Pieralice S, Carlone A, Pozzilli P, Buzzetti R. "Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy." *Diabetes Care*. Vol. 43, n. 8, pp: e86-e87. Aug 2020. DOI: 10.2337/dc20-0954. PMID: 32503838
59. Cavallari I, **Maddaloni E** (first author equal contribution), Pieralice S, Mulè MT, Buzzetti R, Ussia GP, Pozzilli P, Grigioni F. "The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments." *J Clin Endocrinol Metab*. Vol. 105, n. 9, pp: dgaa427. Sep 2020. DOI: 10.1210/clinem/dgaa427. PMID: 32615596
60. Strollo R, **Maddaloni E** (first author equal contribution), Dauriz M, Pedone C, Buzzetti R, Pozzilli P. "Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among Covid-19 deaths." *Diabetes Res Clin Pract*. n.171, pp: 108444. Jan 2021. DOI: 10.1016/j.diabres.2020.108444, PMID: 32946854
61. **Maddaloni E**, D'Onofrio L, Alessandri F, Mignogna C, Leto G, Pascarella G, Mezzaroma I, Lichtner M, Pozzilli P, Agrò FE, Rocco M, Pugliese F, Lenzi A, Holman RR, Mastroianni CM,

- Buzzetti R; CoViDiab Study Group. "Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)". *Cardiovasc Diabetol*. Vol. 19, n. 1, pp: 164, Oct 2020
DOI:10.1186/s12933-020-01140-2. PMID: 33004045
62. **Maddaloni E**, D'Onofrio L, Alessandri F, Mignogna C, Leto G, Coraggio L, Sterpetti S, Pascarella G, Mezzaroma I, Lichtner M, Pozzilli P, Eugenio Agrò F, Rocco M, Pugliese F, Maria Mastroianni C, Buzzetti R; CoViDiab Study group. "Clinical features of patients with type 2 diabetes with and without Covid-19: a case control study (CoViDiab I)." *Diabetes Res Clin Pract*. Vol. 169, pp: 108454, Nov 2020. doi: 10.1016/j.diabres.2020.108454. PMID: 32971157
63. **Maddaloni E**, Moretti C, Del Toro R, Sterpetti S, Ievoli MV, Arnesano G, Strollo R, Briganti SI, D'Onofrio L, Pozzilli P, Buzzetti R. "Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: A cross-sectional study." *Diabet Med*. Vol. 38, n. 2, pp:e14455. Feb 2021. doi: 10.1111/dme.14455. PMID: 33170958.
64. D'Onofrio L, Mignogna C, Carlone A, Bellizzi E, Di Guida M, Moretti C, Zampetti S, Leto G, **Maddaloni E (corresponding author)**, Buzzetti R. "Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: a 24 months follow-up study." *Diabetes Res Clin Pract*. Vol. 173, pp:108681, Mar 2021. doi: 10.1016/j.diabres.2021.108681. PMID: 33516784
65. Mahrooz A, Muscogiuri G, Buzzetti R, **Maddaloni E**. "The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism". *Endocrine*. Vol. 72, n. 2, pp:317-325. May 2021 doi: 10.1007/s12020-021-02729-7. PMID: 33886062
66. Nusca A, Tuccinardi D, Peralice S, Giannone S, Carpenito M, Monte L, Watanabe M, Cavallari I, **Maddaloni E**, Ussia GP, Manfrini S, Grigioni F. "Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease." *Front Pharmacol* eCollection 2021, Vol. 12, pp: 670155. May 2021. doi: 10.3389/fphar.2021.670155. PMID: 34054542
67. **Maddaloni E**, Briganti SI, Crescenzi A, Beretta Anguissola G, Perrella E, Taffon C, Palermo A, Manfrini S, Pozzilli P, Lauria Pantano A. "Usefulness of Color Doppler Ultrasonography in the Risk Stratification of Thyroid Nodules". *European Thyroid Journal*. Vol. 10, n. 4, pp: 339-344. Jul 2021. DOI: 10.1159/000509325. PMID: 34395306.
68. D'Onofrio L, Peralice S, **Maddaloni E**, Mignogna C, Sterpetti S, Coraggio L, Luordi C, Guarisco G, Leto G, Leonetti F, Manfrini S, Buzzetti R. "Effect of COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study." *Diabetes Obes Metab*. Vol. 23, N.7, pp: 1624-1630. Jul 2021. doi: 10.1111/dom.14380. PMID: 33764666
69. Del Toro R, Cavallari I, Tramontana F, Park K, Strollo R, Valente L, De Pascalis M, Grigioni F, Pozzilli P, Buzzetti R, Napoli N, **Maddaloni E**. "Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity." *Endocrine*. Vol. 73, n.2, pp: 339-346, Aug 2021. Doi: 10.1007/s12020-021-02736-8. PMID: 33948786.
70. **Maddaloni E**, D'Onofrio L, Siena A, Luordi C, Mignogna C, Amendolara R, Cavallari I, Grigioni F, Buzzetti R. "Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19: a systematic review and meta-analysis." *Internal and Emergency Medicine* Vol. 16, n. 7, pp: 1975-1985. Oct 2021. Doi: 10.1007/s11739-021-02804-x. PMID: 34273056.
71. D'Onofrio L, Coraggio L, Zurru A, Carlone A, Mignogna C, Moretti C, **Maddaloni E**, Buzzetti R. "Short-term safety profile of Sars-Cov2 vaccination on glucose control: continuous glucose monitoring data in people with autoimmune diabetes". *Diabetes Res Clin Pract*. 179, pp109022. Sep 2021. Doi: 10.1016/j.diabres.2021.109022. PMID: 34450248
72. Cavallari I, **Maddaloni E**, Gragnano F, Patti G, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Marcucci R; START-ANTIPLATELET collaborators. "Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary

- syndrome." *Intern Emerg Med*. Vol. 16, n. 6, pp: 1583-1591. Sep 2021. doi: 10.1007/s11739-021-02640-z. PMID: 33616877
73. Cavallari I, **Maddaloni E**, Grigioni F. "Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter?" *Eur J Prev Cardiol*. Vol. 28, n. 15, pp: 1670-1672. Dec 2021. doi: 10.1093/eurjpc/zwaa153. PMID: 33624108.
74. Mignogna C, **Maddaloni E**, D'Onofrio L, Buzzetti R. "Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes". *Expert Opin Investig Drugs*. Vol. 30, n. 12, pp: 1209-1219. Dec 2021. DOI: 10.1080/13543784.2022.2022119. PMID: 34936848
75. Nusca A, Bernardini F, Mangiacapra F, **Maddaloni E**, Melfi R, Ricottini E, Piccirillo F, Manfrini S, Ussia GP, Grigioni F. "Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study." *J Diabetes Res*. Vol. eCollection2021, n.2021, pp:4952447. Dec 2021. doi: 10.1155/2021/4952447. PMID: 35005029
76. Siddiqui K, **Maddaloni E**. "Editorial: The Changing Panorama of Diabetes Outcomes: Novel Complications and Novelty in Classical Complication." *Front Endocrinol (Lausanne)*. Vol. eCollection2021, n.12, pp: 816481. Jan 2022. doi: 10.3389/fendo.2021.816481. PMID: 35095775
77. Cavallari I, **Maddaloni E**, Nusca A, Tuccinardi D, Buzzetti R, Pozzilli P, Grigioni F. "SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness". *Am J Cardiovasc Drugs*. Vol. 22, n. 3, pp:263-267, May 2022. doi: 10.1007/s40256-021-00508-3. PMID: 34786655
78. Cavallari I, Patti G, **Maddaloni E**, Veneziano F, Mangiacapra F, Ricottini E, Buzzetti R, Ussia GP, Grigioni F. "Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status." *Am J Cardiol*. Vol. 171, pp: 49-54. May 2022. doi: 10.1016/j.amjcard.2022.01.057. PMID: 35277255
79. Tiberti C, D'Onofrio L, Panimolle F, Zampetti S, **Maddaloni E**, Buzzetti R. "Immunoreactivities against different Tyrosine-Phosphatase 2 (IA-2₍₂₅₆₋₇₆₀₎) protein domains characterize distinct phenotypes in subjects with LADA". *Front Endocrinol* Vol. 34, pp: 921886. June 2022. doi: 10.3389/fendo.2022.921886. PMID: 35813648.
80. Alhamar G, **Maddaloni E**, Al Shukry A, Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S, Al-Shammari AA, Abu-Farha M, Abubaker J, Alattar AT, AlOzairi E, Alessandri F, D'Onofrio L, Leto G, Mastroianni CM, Mignogna C, Pascarella G, Pugliese F, Ali H, Al Mulla F, Buzzetti R, Pozzilli P. "Development of a clinical risk score to predict death in patients with COVID-19." *Diabetes Metab Res Rev* Vol. 38, n. 5, pp: e3526, Jul 2022. doi: 10.1002/dmrr.3526. PMID: 35262260.
81. Park K, Li Q, Lynes MD, Yokomizo H, **Maddaloni E**, Shinjo T, St-Louis R, Li Q, Katagiri S, Fu J, Clermont A, Park H, Wu IH, Yu MG, Shah H, Tseng YH, King GL. "Endothelial Cells Induced Progenitors Into Brown Fat to Reduce Atherosclerosis". *Circ Res*. Vol 131, n. 2, pp: 168-183, Jul 2022 doi: 10.1161/CIRCRESAHA.121.319582. PMID: 35642564.
82. Leto G, Tartaglione L, Rotondi S, Pasquali M, **Maddaloni E**, Mignogna C, D'Onofrio L, Zampetti S, Carlone A, Muci ML, Mastroluca D, Fassino V, Buzzetti R, Mazzaferro S. "Diastolic Pressure And Acr Are Modifiable Risk Factors Of Arterial Stiffness In T2DM Without Cardiovascular Disease." *J Clin Endocrinol Metab*. Vol. 107, n. 9, pp: e3857-e3865, Aug 2022 1. doi: 10.1210/clinem/dgac291. PMID: 35595474
83. Defeudis G, **Maddaloni E (first-author equal contribution)**, Rossini G, Di Tommaso AM, Mazzilli R, Di Palma P, Pozzilli P, Napoli N. "Glycemic Variability in Subjects with Diabetes and Hypogonadism during Testosterone Replacement Treatment: A Pilot Study." *J Clin Med*. Vol. 11, n. 18, pp: 5333. Sept 2022. doi: 10.3390/jcm11185333. PMID: 36142982
84. Buzzetti R, **Maddaloni E**, Gaglia J, Leslie RD, Wong FS, Boehm BO. "Adult-onset autoimmune diabetes." *Nat Rev Dis Primers*. Vol. 8, n. 1, pp: 63. Sept 2022. Doi:

10.1038/s41572-022-00390-6. PMID: 36138034

85. Pignatelli P, Baratta F, Buzzetti R, D'Amico A, Castellani V, Bartimoccia S, Siena A, D'Onofrio L, **Maddaloni E**, Pingitore A, Chiariello GA, Santilli F, Pastori D, Cocomello N, Violi F, Del Ben M, Cammisotto V, Camevale R. "The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study.". *Antioxidants*. Vol. 11, n. 10, pp: 1878. Sept 2022. doi: 10.3390/antiox11101878. PMID: 36290601
86. Cavallari I, Nobile E, De Filippis A, Veneziano F, **Maddaloni E**, Ussia GP, Grigioni F. "Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes". *Diabetes Res Clin Pract*. Vol 191, pp: 110043. Sept 2022. doi: 10.1016/j.diabres.2022.110043. Online ahead of print. PMID: 35985427
87. **Maddaloni E**, Bolli GB, Frier BM, Little RR, Leslie RD, Pozzilli P, Buzzetti R. "C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective". *Diabetes Obes Metab*. Vol. 24, n. 10, pp: 1912-1926. Oct 2022. doi: 10.1111/dom.14785. PMID: 35676794
88. D'Onofrio L, Fogolari M, Amendolara R, Siena A, De Fata R, Davini F, Coraggio L, Mignogna C, Moretti C, **Maddaloni E**, Angeletti S, Buzzetti R. "Reduced early response to SARS-CoV2 vaccination in people with type 1 and type 2 diabetes, a 6 months follow-up study: The CoVaDiab study I". *Diabetes Metab Res Rev*. Vol. 39, n. 3, pp: e3601. Mar 2023. doi: 10.1002/dmrr.3601. PMID: 36533777
89. Del Toro R, Palmese F, Feletti F, Zani G, Minguzzi MT, **Maddaloni E**, Napoli N, Bedogni G, Domenicali M. "Relationship between Muscle Mass, Bone Density and Vascular Calcifications in Elderly People with SARS-CoV-2 Pneumonia". *J Clin Med*. Vol.12, n. 6, pp: :2372. Mar 2023, doi: 10.3390/jcm12062372. PMID: 36983372
90. **Maddaloni E**, Cavallari I, La Porta Y, Appetecchia A, D'Onofrio L, Grigioni F, Buzzetti R, Holman RR. "Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials". *Diabetes Obes Metab*. Vol. 25, n. 5, pp:1341-1350. May 2023. doi: 10.1111/dom.14986 PMID: 36700422
91. **Maddaloni E**, Coraggio L, Amendolara R, Baroni MG, Cavallo MG, Copetti M, Cossu E, D'Angelo P, D'Onofrio L, Cosmo S, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Park K, Holman RR, Trischitta V, Buzzetti R; SUMMER Study in Diabetes Group. "Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes" *Diabetes Metab Res Rev*. Vol. 39, n. 5, pp:e3632, Jul 2023 doi: 10.1002/dmrr.3632. PMID: 36880127
92. Pieralice S, Coppola A, **Maddaloni E**. "Updates on Glycaemic Control Strategies: A Range of Opportunities after Total Pancreatectomy". *J Clin Med*. Vol. 12, n.6, pp: 3306. May 2023. doi: 10.3390/jcm12093306. PMID: 37176746
93. D'Onofrio L, Amendolara R, Mignogna C, Leto G, Tartaglione L, Mazzaferro S, **Maddaloni E**, Buzzetti R. "Lack of association between serum chitotriosidase activity and arterial stiffness in type 2 diabetes without cardiovascular complications". *Int J Mol Sci*. Vol. 2023, n 24, pp: 15809. Oct 2023. doi .3390/ijms242115809
94. **Maddaloni E**, Buzzetti R. "Heterogeneity of Autoimmune Diabetes". *Il Diabete*. Vol. 34, n. 3. pp: 153-161. Oct 2023. Doi: 10.30682/ildia2303a
95. **Maddaloni E**, Carlone A, Pitocco D, Leanza G, Suraci C, Altomare M, Cavallo MG, Barchetta I, Morano S, Moretti C, Coraggio L, Visalli N, Tramontana F, Schiaffini R, Crinò A, Buzzetti R, Pozzilli P, for the IMDIAB study group. "Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow-up study". *Diabetes Obes Metab*. Vol. 25, n.11, pp: 3415-3419. Nov 2023 Doi: 10.1111/dom.15213. PMID: 38014612

96. **Maddaloni E**, Naci AM, Mignogna C, Galiero R, Amendolara R, Fogolari M, Satta C, Serafini C, Angeletti S, Cavallo MG, Cossu E, Sasso FC, Buzzetti R, Pozzilli P; LADASAXADAPA study group. "Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of β -cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study". *Diabetes Obes Metab*. 2024 Jan 31. doi: 10.1111/dom.15469. PMID: 38297915. Online ahead of print.
97. **Maddaloni E**, Amendolara R, Balena A, Latino A, Sessa RL, Buzzetti R. "Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes." *Expert Opin Investig Drugs*. 2024 Mar 13:1-16. doi: 10.1080/13543784.2024.2326036. Online ahead of print. PMID: 38427915

Full papers as member of the IMDIAB study group

1. Di Stasio E, Maggi D, Berardesca E, Marulli GC, Bizzarri C, Lauria A, Portuesi R, Cavallo MG, Costantino F, Buzzetti R, Astorri E, Pitocco D, Songini M, Pozzilli P; **IMDIAB Group**. "Blue eyes as a risk factor for type 1 diabetes." *Diabetes Metab Res Rev*. Vol. 27, no. 6, pp: 609-13 Sep 2011. IF: 3.064

Full papers as member of the TRIGR study group

1. Nucci AM, Virtanen SM, Sorkio S, Bärlund S, Cuthbertson D, Uusitalo U, Lawson ML, Salonen M, Berseth CL, Ormiston A, Lehtonen E, Savilahti E, Becker DJ, Dupré J, Krischer JP, Knip M, Åkerblom HK; **TRIGR Investigators**. Regional differences in milk and complementary feeding patterns in infants participating in an international nutritional type 1 diabetes prevention trial. *Matern Child Nutr*. 2017, 13(3), e12354
2. Knip M et al., Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial. *JAMA*. Vol. 319, n. 1, pp: 38-48. Jan 2018
3. Nucci AM, Virtanen SM, Cuthbertson D, Ludvigsson J, Einberg U, Huot C, Castano L, Aschemeier B, Becker DJ, Knip M, Krischer JP; TRIGR Investigators. "Growth and development of islet autoimmunity and type 1 diabetes in children genetically at risk". *Diabetologia* 2021,
4. Ludvigsson J, Cuthbertson D, Becker DJ, Kordonouri O, Aschemeier B, Pacaud D, Clarson C, Krischer JP, Knip M; TRIGR Investigators. "Increasing plasma glucose before the development of type 1 diabetes - the TRIGR study.". *Pediatr Diabetes*. 2021 Aug 9. doi: 10.1111/pedi.13251. Online ahead of print. PMID: 34369627

Book chapters

1. **Maddaloni E**, Pozzilli P. 2Tipo 1 e LADA in crescita: prevenzione e assistenza ottimale" [*Italian*], in Bonora E, Sesti G "Il Diabete in Italia, Società Italiana di Diabetologia", Bononia University Press, pp 157-164, 2016.
2. **Maddaloni E**, Strollo R, Pozzilli P. "Il ruolo del biostatistico nella preparazione conduzione e monitoraggio delle sperimentazioni cliniche" [*Italian*], in Alloni R, D'Aprile M "Guida pratica per lo sperimentatore clinico", Aracne Editrice, pp 29-34, 2017. DOI:10.4399/97888548982576
3. **Maddaloni E**, Tabacco G. "Patologie dell'asse ipotalamo-adeno ipofisario e malattie della neuro-ipofisi" (Italian), in Pozzilli P "L'endocrinologia del Campus Bio-Medico", Edizioni Minerva Medica. Chapter 3
4. Palermo A, **Maddaloni E**. "Dislipidemie" in Pozzilli P "L'endocrinologia del Campus Bio-Medico", Edizioni Minerva Medica. Chapter 7.
5. **Maddaloni E**, D'Onofrio L, Buzzetti R. "Diabete mellito tipo 1 e altri tipi di diabete mellito" in "Manuale di endocrinologia" a cura di A. Lenzi e delle scuole romane di endocrinologia, Carocci Editore, Edizione 2023.

Abstracts and posters

Dr Maddaloni is author of several abstracts and posters in national and international scientific meeting.

"Ai sensi e per gli effetti degli artt. 46 e 47 del D.P.R. n. 445 del 28 dicembre 2000 e consapevole delle sanzioni penali nel caso di dichiarazioni mendaci, di formazione o uso di atti falsi richiamate dall'art. 76 del D.P.R. 445/2000, il sottoscritto Ernesto Maddaloni, nato a San Giorgio a Cremano il 24/7/1986, dichiara che i dati contenuti nel presente documento corrispondono a verità. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi e per gli effetti del d. lgs. 30 giugno 2003 n°196 e del GDPR 679/16".

Date and signature 27 Mar 2024